Pma/510 (k) #: (b)(4).Incident requires fda mdr report based on the surgical intervention carried out due to the occurrence of restenosis in the lesion where a ptx stent was indwelling.The device involved in this complaint is as follows: ziv6-35-125-6.0-120-ptx of lot number c778568.The stent in question remains implanted in the pt and therefore is not available for eval.With the info provided, a document based investigation was carried out.No images in relation to the reported event were provided.It may be noted that restenosis is a common adverse event of endovascular procedures and can be caused by injury to the vessel (e.G.During pta and/or stenting).Vessel injury provokes an inflammatory response that leads (or amplifies) to the restenosis process.Restenosis of the stented artery is a known potential adverse event associated with the placement of this device.Prior to distribution all zilver ptx devices are subject to visual inspection and functional checks to ensure device integrity.A review of the relevant manufacturing records for zilver ptx devices revealed no discrepancies which could have contributed to this complaint issue.Due to the lack of images for review and as the conditions of use cannot be replicated in a laboratory setting, it is not possible to conclusively determine the root cause for this complaint at this time.The complaint is confirmed based on customer testimony.As per the info provided following pta, the pt recovered.The risk associated with this complaint has been assessed by quality engineering and determined to be low.Complaints of this nature will continue to be monitored for potential emerging trends.
|